Disease · EFO_0008501

dysplasia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. dysplasia. Diseases, record EFO_0008501. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0008501

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: dysplasia; Open Targets
Open Targets ID: EFO_0008501; Open Targets
Other names: dyscrasia, dysplastic; Open Targets
NCI Thesaurus: C4086; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 1 of its 4 drugs, from TTD; Open Targets

Drugs4

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
BIZALIMOGENE RALAPLASMID	CHEMBL4297247	Gene	Phase 3	TTD	1	0	0	Drugs and targets
PYRVINIUM	CHEMBL1201303	Small molecule	Phase 2	ClinicalTrials.gov	1	1	1	Drugs and targets
HPPH	CHEMBL500853	Small molecule	Phase 1	ClinicalTrials.gov	3	3	3	Drugs and targets
PORFIMER SODIUM	CHEMBL1201481	Small molecule	Unknown	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets0

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

None in this release.

Trials5

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00530088	Photodynamic Therapy Using Porfimer Sodium in Treating Patients With Recurrent Mouth or Throat Dysplasia or Recurrent In Situ Cancer or Stage I Cancer of the Mouth or Throat	Not applicable	30	2014-07-04	Head and Neck Cancer	PORFIMER SODIUM	Its record names the disease	ClinicalTrials.gov
NCT06782048	Use of Pyrvinium to Reverse Stomach Precancerous Conditions	Phase 2	50		STOMACH NEOPLASM	PYRVINIUM	Its record names the disease	ClinicalTrials.gov
NCT00675233	Photodynamic Therapy Using HPPH in Treating Patients With Dysplasia, Cancer in Situ, or Invasive Cancer of the Larynx	Phase 1	29		Head and Neck Cancer	HPPH	Its record names the disease	ClinicalTrials.gov
NCT01140178	A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx	Phase 1	29		Dysplasia, Carcinoma of the Oral Cavity, Carcinoma of the Oropharynx	HPPH	Its record names the disease	ClinicalTrials.gov
NCT00670397	Photodynamic Therapy Using HPPH in Treating Patients With Recurrent Dysplasia, Carcinoma in Situ, or Stage I Oral Cavity Cancer	Phase 1	11		Head and Neck Cancer	HPPH	Its record names the disease	ClinicalTrials.gov

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials1

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it
19687399	RESULT	1

Source PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0008501

GET https://conductscience.org/api/diseases/v1/EFO_0008501/drugs

API reference For AI assistants